Virax soars on positive Phase II results
16 October, 2003 by Melissa TrudingerVirax's share price (ASX:VHL) soared 28 per cent today on heavy trading after the company released good results for its HIV immunotherapy Phase IIa clinical trial.
GroPep to receive $3.8m at malaria milestone
16 October, 2003 by Melissa TrudingerAdelaide-based biotech GroPep is to receive AUD$3.8 million from the Gates Foundation-funded Malaria Vaccine Initiative (MVI) and the Program for Appropriate Technology in Health (PATH), after meeting the first milestone in a project inherited from Biotech Australia.
ComBio 2003: Hormone shows promise as metabolism regulator
30 September, 2003 by Melissa TrudingerA fat-derived hormone identified using proteomic techniques may have therapeutic uses related to its role as a regulator of lipid metabolism in the liver and arteries.
Pharmaxis reveals IPO plans
26 September, 2003 by Melissa TrudingerPharmaxis has announced plans for a AUD$21 million float on the ASX in October/November.
Blis Technologies aims at Chinese market
23 September, 2003 by Graeme O'NeillDunedin (NZ) biotech company Blis Technologies has opened a portal into a potential $200 million market by signing a deal with Auckland-based Asia Pacific Biotech Distributors (APBD) to take its antibacterial Throat Guard into China.
WEHI team exposes two new anti-cancer targets
19 September, 2003 by Graeme O'NeillCancer researchers in Melbourne and Innsbruck hunting for new options to treat cancer have flushed two promising new therapeutic targets from the genetic thickets of the p53-mediated apoptosis pathway: Puma and Noxa.
Diabetes researcher Zimmett honoured
19 September, 2003 by Tanya HollisDiabetes luminary Prof Paul Zimmet has been honoured by his peers, receiving the Kellion Award for his contribution to the field.
pSivida claims success in anti-tumour device study
19 September, 2003 by Tanya HollisA nano-structured silicon device containing slow-release radiotherapy has successfully halted tumours in an animal study.
Peplin spruiks promising new compound
16 September, 2003 by Graeme O'NeillBrisbane's Peplin Biotech Ltd (ASX:PEP) has had a good week, reporting a promising new indication for its lead anti-cancer compound PEP005, and promising activity from a new compound of undisclosed provenance.
Monash researchers claim key MS find
15 September, 2003 by Graeme O'NeillMonash University researchers have solved the crystal structure of the protein suspected to be the focus of the autoimmune attack that destroys the fatty insulating sheath around neurons in the brain in multiple sclerosis (MS).
Solbec claims cancer success with plant extract
08 September, 2003 by Graeme O'NeillWestern Australian biotech company Solbec Pharmaceuticals (ASX:SBP) may have struck therapeutic gold in a thorny wayside weed called devil's apple (Solanum linnaeanum) .
Bionomics upbeat despite bigger annual loss
05 September, 2003 by Graeme O'NeillAdelaide epilepsy specialist Bionomics (ASX:BNO) has reported an after-tax loss of $4.54 million for the year to June 30, up from $3.49 million in 2001-02.
Monash launches new brain research centre
05 September, 2003 by Melissa TrudingerMonash University yesterday launched its new Centre for Brain and Behaviour, bringing together more than 150 researchers including students and postdocs from 21 university departments and research centres.
Eiffel signs US insulin trial deal
05 September, 2003 by Graeme O'NeillMelbourne drug re-engineering company Eiffel Technologies (ASX:EIF) has signed an agreement with a large US drug-delivery company to trial an inhalable form of insulin produced by Eiffel's proprietary supercritical fluid technology.
Arthritis CRC picks up new funding and partners
03 September, 2003 by Melissa TrudingerThe Cooperative Research Centre for Chronic Inflammatory Diseases has received AUD$5 million in supplementary funding from the federal government to implement two new programs.
